Histogenics pushes cartilage products with $9m
This article was originally published in Clinica
Cartilage regeneration specialist Histogenics is advancing clinical development of its flagship products after raising $9m in a series B financing round led by Boston Millennia Partners. This latest influx of funds brings the total investment in the company to around $24m. Waltham, Massachusetts-based Histogenics is currently carrying out clinical trials of its NeoCart neocartilage implant and the VeriCart treatment to help regenerate cartilage.